MicroRNA于弥漫大B细胞淋巴瘤诊疗中的作用

doi:10.20047/j.issn1673-7210.2022.29.08

摘要
图/表
参考文献(34)
相关文章 (15)

全文: PDF (632 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 MicroRNA（miRNA）是一类内生的、分布广泛、长度为20～24个核苷酸组成的非编码RNA，广泛存在于体液中。miRNA在恶性肿瘤中参与多种信号通路传导及靶基因的调节，在肿瘤的发生、发展、侵袭、转移中发挥重要的作用。弥漫大B细胞淋巴瘤（DLBCL）发病机制复杂，目前仍不清楚，探索miRNA在DLBCL发生发展、治疗及预后中的作用，对新药物的研发及发现预后新指标具有重要的意义。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张翰钰1 李敬东2

关键词 ：弥漫大B细胞淋巴瘤, MicroRNA, 肿瘤微环境, 预后

Abstract：MicroRNA(miRNA) is a class of endogenous, widely distribute, and non-coding RNAs with a length of 20 to 24 nucleotides, which is widely present in body fluids. miRNA is involved in various signaling pathways and the regulation of target genes in malignant tumors, and plays an important role in the occurrence, development, invasion and metastasis of tumors. The pathogenesis of diffuse large B-cell lymphoma (DLBCL) is complex and still unclear. Exploring the role of miRNA in the development, treatment and prognosis of DLBCL is of great significance for the development of new drugs and the discovery of new prognostic indicators.

Key words： Diffuse large B-cell lymphoma MicroRNA Tumor microenvironment Prognosis

基金资助:河南省医学科技攻关计划（联合共建）项目（LHGJ20190434）。

通讯作者: 李敬东（1968.11-），男，博士，教授；研究方向：恶性淋巴瘤的诊治。

作者简介: 张翰钰（1995.12-），女，河南省新乡医学院第一临床学院2019级血液内科学专业在读硕士研究生；研究方向：弥漫大B细胞淋巴瘤的诊断。

引用本文:

张翰钰1 李敬东2. MicroRNA于弥漫大B细胞淋巴瘤诊疗中的作用[J]. 中国医药导报, 2022, 19(29): 38-41,49.
ZHANG Hanyu1 LI Jingdong2. The role of microRNA in the diagnosis and treatment of diffuse large B-cell lymphoma. 中国医药导报, 2022, 19(29): 38-41,49.

链接本文:

https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2022.29.08 或 https://www.yiyaodaobao.com.cn/CN/Y2022/V19/I29/38

[1] Sehn LH，Salles G. Diffuse Large B-Cell Lymphoma [J]. N Engl J Med，2021，384（9）：842-858.
[2] Thandra KC，Barsouk A，Saginala K，et al. Epidemiology of Non-Hodgkin’s Lymphoma [J]. Med Sci （Basel），2021， 9（1）：5.
[3] Caner V，Cetin GO，Hacioglu S，et al. The miRNA content of circulating exosomes in DLBCL patients and in vitro influence of DLBCL-derived exosomes on miRNA expression of healthy B-cells from peripheral blood [J]. Cancer Biomark，2021，32（4）：519-529.
[4] Zhu L，Sun HT，Wang S，et al. Isolation and characterization of exosomes for cancer research [J]. J Hematol Oncol，2020，13（1）：152.
[5] Pan BT，Johnstone RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro：selective externalization of the receptor [J]. Cell，1983，33（3）：967-978.
[6] Lv X，Li Y，Li H，et al. Molecular function predictions and diagnostic value analysis of plasma exosomal miRNAs in Hirschsprung’s disease [J]. Epigenomics，2020，12（5）：409-422.
[7] Ishola AA，La’ah AS，Le HD，et al. Non-coding RNA and lung cancer progression [J]. J Chin Med Assoc，2020，83（1）：8-14.
[8] Bartel DP. Metazoan MicroRNAs [J]. Cell，2018，173（1）：20-51.
[9] Tastan B，Tarakcioglu E，Birinci Y，et al. Role of Exosomal MicroRNAs in Cell-to-Cell Communication [J]. Methods Mol Biol，2022，2257：269-292.
[10] Shaffer AL，Young RM，Staudt LM. Pathogenesis of human B cell lymphomas [J]. Annu Rev Immunol，2012， 30：565-610.
[11] Zhu FQ，Zeng L，Tang N，et al. MicroRNA-155 Downregulation Promotes Cell Cycle Arrest and Apoptosis in Diffuse Large B-Cell Lymphoma [J]. Oncol Res，2016，24（6）：415-427.
[12] Stanilov N，Grigorova A，Velikova T，et al. Genetic variation of TGF-ΒR2 as a protective genotype for the development of colorectal cancer in men [J]. World J Gastrointest Oncol，2021，13（11）：1766-1780.
[13] Li XD，Li XM，Gu JW，et al. MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway [J]. Eur Rev Med Pharmacol Sci，2020，24（14）：7577.
[14] Rai D，Kim SW，Mckeller MR，et al. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis [J]. Proc Natl Acad Sci U S A，2010，107（7）：3111-3116.
[15] Zheng Z，Sun R，Zhao HJ，et al. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells [J]. Mol Cancer，2019，18（1）：54.
[16] Xu Y，Liu Z，Lv L，et al. MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8+T lymphocytes in human diffuse large B cell lymphoma [J]. J Exp Clin Cancer Res，2020，39（1）：238.
[17] 李敬东，韩效林，杨翠，等.miR-34b-5p上调抑制弥漫大B细胞淋巴瘤的侵袭及RhoA/ROCK信号通路[J]. 安徽医科大学学报，2021，56（2）：186-190.
[18] Bautista-Sánchez D，Arriaga-Canon C，Pedroza-Torres A，et al. The Promising Role of miR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics [J]. Mol Ther Nucleic Acids，2020，20：409-420.
[19] Kapoor I，Bodo J，Hill BT，et al. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance [J]. Cell Death Dis，2020，11（11）：941.
[20] Zheng Z，Xu PP，Wang L，et al. MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells [J]. J Exp Clin Cancer Res，2017，36（1）：82.
[21] Wang L，Li LR，Young KH. New agents and regimens for diffuse large B cell lymphoma [J]. J Hematol Oncol，2020， 13（1）：175.
[22] Cheng M，Zain J，Rosen ST，et al. Emerging drugs for the treatment of cutaneous T-cell lymphoma [J]. Expert Opin Emerg Drugs，2022，27（1）：45-54.
[23] Anastasiadou E，Seto AG，Beatty X，et al. Cobomarsen，an Oligonucleotide Inhibitor of miR-155，Slows DLBCL Tumor Cell Growth In Vitro and In Vivo [J]. Clin Cancer Res，2021，27（4）：1139-1149.
[24] Huang WT，Kuo SH，Kuo YC，et al. miR-155-regulated mTOR and Toll-like receptor 5 in gastric diffuse large B-cell lymphoma [J]. Cancer Med，2022，11（3）：555-570.
[25] Bartolomé-Izquierdo N，De Yébenes VG，?譧lvarez-Prado AF，et al. miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma [J]. Blood，2017，129（17）：2408-2419.
[26] Pan G，Liu Y，Shang L，et al. EMT-associated microRNAs and their roles in cancer stemness and drug resistance [J]. Cancer Commun （Lond），2021，41（3）：199-217.
[27] Wang R，Shen J，Wang Q，et al. Bortezomib inhibited the progression of diffuse large B-cell lymphoma via targeting miR-198 [J]. Biomed Pharmacother，2018，108：43-49.
[28] Wang S，Wang L，Hu J，et al. Outcomes in refractory diffuse large B-cell lymphoma：results from a multicenter real-world study in China [J]. Cancer Commun （Lond），2021，41（3）：229-239.
[29] Lee B，Lee H，Cho J，et al. Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma [J]. Front Oncol，2021，11：628807.
[30] Berendsen MR，Stevens WBC，Van Den Brand M，et al. Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma：Insight into Mechanisms of Therapy Resistance [J]. Cancers，2020，12（12）：3553.
[31] Sun R，Zheng Z，Wang L，et al. A novel prognostic model based on four circulating miRNA in diffuse large B-cell lymphoma：implications for the roles of MDSC and Th17 cells in lymphoma progression [J]. Mol Oncol，2021，15（1）：246-261.
[32] Hu M，Wang X，Liu N，et al. Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients [J]. Biosci Rep，2021，41（7）：BSR20201551.
[33] Rinaldi F，Marchesi F，Palombi F，et al. MiR-22，a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients [J]. Br J Haematol，2021，195（3）：399-404.
[34] Ahmadvand M，Eskandari M，Pashaiefar H，et al. Over expression of circulating miR-155 predicts prognosis in diffuse large B-cell lymphoma [J]. Leuk Res，2018，70：45-48.